Physician profile
Daniel K Jass
NPI 1184715542
$2,756.36
in general payments reported to CMS, 2019-2025
23 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $294 · 2021: $439 · 2022: $589 · 2023: $237 · 2024: $236 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195 · Education: $14.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.23 |
| Education | $14.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $677.36 | 2019-2025 | |
| Harmony Biosciences LLC | $539.59 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $390.13 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $176.37 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Avadel Cns Pharmaceuticals, LLC | $154.15 | 2023-2025 | Lumryz |
| Lilly USA, LLC | $144.11 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $107.81 | 2019-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $74.41 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $60.44 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bausch Health US, LLC | $59.62 | 2021-2023 | Wellbutrin, Aplenzin |
| Exact Sciences Corporation | $57.45 | 2024-2025 | Cologuard Collection Kit |
| Aytu Biopharma, INC. | $52.76 | 2019-2020 | |
| Pfizer INC. | $52.10 | 2024-2025 | |
| Axsome Therapeutics, INC. | $29.50 | 2023-2024 | Sunosi |
| Avanir Pharmaceuticals, INC. | $28.87 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $27.96 | 2021 | |
| Genentech USA, INC. | $27.49 | 2020-2021 | |
| Dexcom, INC. | $21.71 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.77 | 2024 | Synjardy, Jardiance |
| Eisai INC. | $15.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.94 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $13.71 | 2025 | Voquezna |
| Metuchen Pharmaceuticals | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.